Skip to main content
Top
Published in: World Journal of Urology 8/2016

01-08-2016 | Original Article

Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy

Authors: Mary E. Westerman, Boris Gershman, R. Jeffrey Karnes, R. Houston Thompson, Laureano Rangel, Stephen A. Boorjian

Published in: World Journal of Urology | Issue 8/2016

Login to get access

Abstract

Purpose

While a family history (FH) of prostate cancer represents an established risk factor for prostate cancer diagnosis, conflicting data exist regarding the oncologic importance of FH. Herein, we evaluated the association of FH with clinicopathologic outcomes among men undergoing radical prostatectomy (RP).

Methods

We identified 16,472 men who underwent RP between 1987 and 2010 at Mayo Clinic. Patients were considered to have a positive FH if at least one first-degree relative had been diagnosed with prostate cancer. Survival was estimated using the Kaplan–Meier method. The associations of FH with clinicopathologic features and survival were evaluated using logistic and Cox regression analyses.

Results

Overall, 5323 (32.3 %) men reported a FH of prostate cancer. Median follow-up was 9.9 years (IQR 5.9, 15.5). Patients with a FH were significantly more likely to have low-risk disease (47.7 vs. 43.0 %; p < 0.0001) and were significantly more likely to have organ-confined disease at RP (79.2 vs. 74.4 %; p < 0.0001). Men with FH had a significantly higher 10-year cancer-specific (99 vs. 97 %; p < 0.001) and overall survival (92 vs. 85 %; p < 0.001) than men without FH. Moreover, on multivariable analysis, FH of prostate cancer remained independently associated with reduced cancer-specific (HR 0.68; p = 0.003) and all-cause mortality (HR 0.69; p < 0.0001).

Conclusion

In this surgical population, FH of prostate cancer was associated with lower-risk disease at diagnosis, more favorable pathology at RP, and significantly better cancer-specific and overall survival. These results may be utilized for patient counseling.
Literature
2.
go back to reference Kupelian PA, Kupelian VA, Witte JS, Macklis R, Klein EA (1997) Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. J Clin Oncol 15:1478–1480PubMed Kupelian PA, Kupelian VA, Witte JS, Macklis R, Klein EA (1997) Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. J Clin Oncol 15:1478–1480PubMed
3.
go back to reference Fincham SM, Hill GB, Hanson J, Wijayasinghe C (1990) Epidemiology of prostatic cancer: a case-control study. Prostate 17:189–206CrossRefPubMed Fincham SM, Hill GB, Hanson J, Wijayasinghe C (1990) Epidemiology of prostatic cancer: a case-control study. Prostate 17:189–206CrossRefPubMed
4.
go back to reference Johns LE, Houlston RS (2003) A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 91:789–794CrossRefPubMed Johns LE, Houlston RS (2003) A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 91:789–794CrossRefPubMed
5.
go back to reference Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P (2003) Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer 107:797–803CrossRefPubMed Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P (2003) Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer 107:797–803CrossRefPubMed
6.
go back to reference Liss MA, Chen H, Hemal S, Krane S, Kane CJ, Xu J, Kader AK (2015) Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening. J Urol 193:75–79CrossRefPubMed Liss MA, Chen H, Hemal S, Krane S, Kane CJ, Xu J, Kader AK (2015) Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening. J Urol 193:75–79CrossRefPubMed
7.
go back to reference Saarimaki L, Tammela TL, Maattanen L, Taari K, Kujala PM, Raitanen J, Auvinen A (2014) Family history in the finnish prostate cancer screening trial. Int J Cancer. doi:10.1002/ijc.29243 PubMed Saarimaki L, Tammela TL, Maattanen L, Taari K, Kujala PM, Raitanen J, Auvinen A (2014) Family history in the finnish prostate cancer screening trial. Int J Cancer. doi:10.​1002/​ijc.​29243 PubMed
8.
go back to reference Azzouzi AR, Valeri A, Cormier L, Fournier G, Mangin P, Cussenot O (2003) Familial prostate cancer cases before and after radical prostatectomy do not show any aggressiveness compared with sporadic cases. Urology 61:1193–1197CrossRefPubMed Azzouzi AR, Valeri A, Cormier L, Fournier G, Mangin P, Cussenot O (2003) Familial prostate cancer cases before and after radical prostatectomy do not show any aggressiveness compared with sporadic cases. Urology 61:1193–1197CrossRefPubMed
9.
go back to reference Bauer JJ, Srivastava S, Connelly RR, Sesterhenn IA, Preston DM, McLeod DG, Moul JW (1998) Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. Urology 51:970–976CrossRefPubMed Bauer JJ, Srivastava S, Connelly RR, Sesterhenn IA, Preston DM, McLeod DG, Moul JW (1998) Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. Urology 51:970–976CrossRefPubMed
10.
go back to reference Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Zincke H, Blute ML (2006) Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy. J Urol 176:1118–1121CrossRefPubMed Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Zincke H, Blute ML (2006) Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy. J Urol 176:1118–1121CrossRefPubMed
11.
go back to reference Bova GS, Partin AW, Isaacs SD, Carter BS, Beaty TL, Isaacs WB, Walsh PC (1998) Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol 160:660–663CrossRefPubMed Bova GS, Partin AW, Isaacs SD, Carter BS, Beaty TL, Isaacs WB, Walsh PC (1998) Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol 160:660–663CrossRefPubMed
12.
go back to reference Heck MM, Kron M, Gschwend JE, Herkommer K (2012) Effect of family history on outcome in german patients treated with radical prostatectomy for clinically localised prostate cancer. Eur J Cancer 48:1312–1317CrossRefPubMed Heck MM, Kron M, Gschwend JE, Herkommer K (2012) Effect of family history on outcome in german patients treated with radical prostatectomy for clinically localised prostate cancer. Eur J Cancer 48:1312–1317CrossRefPubMed
13.
go back to reference Lee KL, Marotte JB, Ferrari MK, McNeal JE, Brooks JD, Presti JC Jr (2005) Positive family history of prostate cancer not associated with worse outcomes after radical prostatectomy. Urology 65:311–315CrossRefPubMed Lee KL, Marotte JB, Ferrari MK, McNeal JE, Brooks JD, Presti JC Jr (2005) Positive family history of prostate cancer not associated with worse outcomes after radical prostatectomy. Urology 65:311–315CrossRefPubMed
14.
go back to reference Roehl KA, Loeb S, Antenor JA, Corbin N, Catalona WJ (2006) Characteristics of patients with familial versus sporadic prostate cancer. J Urol 176:2438–2442 (discussion 2442) CrossRefPubMed Roehl KA, Loeb S, Antenor JA, Corbin N, Catalona WJ (2006) Characteristics of patients with familial versus sporadic prostate cancer. J Urol 176:2438–2442 (discussion 2442) CrossRefPubMed
15.
go back to reference Roupret M, Fromont G, Bitker MO, Gattegno B, Vallancien G, Cussenot O (2006) Outcome after radical prostatectomy in young men with or without a family history of prostate cancer. Urology 67:1028–1032CrossRefPubMed Roupret M, Fromont G, Bitker MO, Gattegno B, Vallancien G, Cussenot O (2006) Outcome after radical prostatectomy in young men with or without a family history of prostate cancer. Urology 67:1028–1032CrossRefPubMed
16.
go back to reference Sacco E, Prayer-Galetti T, Pinto F, Ciaccia M, Fracalanza S, Betto G, Pagano F (2005) Familial and hereditary prostate cancer by definition in an italian surgical series: clinical features and outcome. Eur Urol 47:761–768CrossRefPubMed Sacco E, Prayer-Galetti T, Pinto F, Ciaccia M, Fracalanza S, Betto G, Pagano F (2005) Familial and hereditary prostate cancer by definition in an italian surgical series: clinical features and outcome. Eur Urol 47:761–768CrossRefPubMed
17.
go back to reference D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974CrossRefPubMed D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974CrossRefPubMed
18.
go back to reference Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H (2001) Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol 165:1146–1151CrossRefPubMed Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H (2001) Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol 165:1146–1151CrossRefPubMed
19.
go back to reference Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, Scardino PT (2006) Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24:3973–3978CrossRefPubMed Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, Scardino PT (2006) Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24:3973–3978CrossRefPubMed
20.
go back to reference Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150:797–802PubMed Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150:797–802PubMed
21.
go back to reference Gronberg H, Isaacs SD, Smith JR, Carpten JD, Bova GS, Freije D, Xu J, Meyers DA, Collins FS, Trent JM, Walsh PC, Isaacs WB (1997) Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (hpc1) locus. JAMA 278:1251–1255CrossRefPubMed Gronberg H, Isaacs SD, Smith JR, Carpten JD, Bova GS, Freije D, Xu J, Meyers DA, Collins FS, Trent JM, Walsh PC, Isaacs WB (1997) Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (hpc1) locus. JAMA 278:1251–1255CrossRefPubMed
22.
go back to reference Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI (1995) Pathological features of hereditary prostate cancer. J Urol 153:987–992CrossRefPubMed Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI (1995) Pathological features of hereditary prostate cancer. J Urol 153:987–992CrossRefPubMed
23.
go back to reference Keetch DW, Humphrey PA, Smith DS, Stahl D, Catalona WJ (1996) Clinical and pathological features of hereditary prostate cancer. J Urol 155:1841–1843CrossRefPubMed Keetch DW, Humphrey PA, Smith DS, Stahl D, Catalona WJ (1996) Clinical and pathological features of hereditary prostate cancer. J Urol 155:1841–1843CrossRefPubMed
24.
go back to reference Kotsis SV, Spencer SL, Peyser PA, Montie JE, Cooney KA (2002) Early onset prostate cancer: predictors of clinical grade. J Urol 167:1659–1663CrossRefPubMed Kotsis SV, Spencer SL, Peyser PA, Montie JE, Cooney KA (2002) Early onset prostate cancer: predictors of clinical grade. J Urol 167:1659–1663CrossRefPubMed
25.
go back to reference Valeri A, Azzouzi R, Drelon E, Delannoy A, Mangin P, Fournier G, Berthon P, Cussenot O (2000) Early-onset hereditary prostate cancer is not associated with specific clinical and biological features. Prostate 45:66–71CrossRefPubMed Valeri A, Azzouzi R, Drelon E, Delannoy A, Mangin P, Fournier G, Berthon P, Cussenot O (2000) Early-onset hereditary prostate cancer is not associated with specific clinical and biological features. Prostate 45:66–71CrossRefPubMed
26.
go back to reference Kupelian PA, Klein EA, Witte JS, Kupelian VA, Suh JH (1997) Familial prostate cancer: a different disease? J Urol 158:2197–2201CrossRefPubMed Kupelian PA, Klein EA, Witte JS, Kupelian VA, Suh JH (1997) Familial prostate cancer: a different disease? J Urol 158:2197–2201CrossRefPubMed
27.
28.
go back to reference Murff HJ, Spigel DR, Syngal S (2004) Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 292:1480–1489CrossRefPubMed Murff HJ, Spigel DR, Syngal S (2004) Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 292:1480–1489CrossRefPubMed
Metadata
Title
Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy
Authors
Mary E. Westerman
Boris Gershman
R. Jeffrey Karnes
R. Houston Thompson
Laureano Rangel
Stephen A. Boorjian
Publication date
01-08-2016
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 8/2016
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-015-1738-6

Other articles of this Issue 8/2016

World Journal of Urology 8/2016 Go to the issue